aqst: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	101,957	20,546
Net increase in cash and cash equivalents	57,517	-11,010
Cash and cash equivalents at beginning of period	71,546	-
Cash and cash equivalents at end of period	129,063	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	101,957	20,546
Net increase in cash and cash equivalents	57,517	-11,010
Cash and cash equivalents at beginning of period	71,546	-
Cash and cash equivalents at end of period	129,063	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Aquestive Therapeutics, Inc. (AQST)